AU1279397A - Modified vegf antisense oligonucleotides - Google Patents

Modified vegf antisense oligonucleotides

Info

Publication number
AU1279397A
AU1279397A AU12793/97A AU1279397A AU1279397A AU 1279397 A AU1279397 A AU 1279397A AU 12793/97 A AU12793/97 A AU 12793/97A AU 1279397 A AU1279397 A AU 1279397A AU 1279397 A AU1279397 A AU 1279397A
Authority
AU
Australia
Prior art keywords
antisense oligonucleotides
modified vegf
vegf antisense
modified
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12793/97A
Inventor
Gregory S Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/569,926 external-priority patent/US5641756A/en
Application filed by Hybridon Inc filed Critical Hybridon Inc
Publication of AU1279397A publication Critical patent/AU1279397A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
AU12793/97A 1995-12-08 1996-12-05 Modified vegf antisense oligonucleotides Abandoned AU1279397A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/569,926 US5641756A (en) 1993-07-27 1995-12-08 Modified VEGF oligonucleotides
US569926 1995-12-08
PCT/US1996/019320 WO1997021808A1 (en) 1995-12-08 1996-12-05 Modified vegf antisense oligonucleotides

Publications (1)

Publication Number Publication Date
AU1279397A true AU1279397A (en) 1997-07-03

Family

ID=24277485

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12793/97A Abandoned AU1279397A (en) 1995-12-08 1996-12-05 Modified vegf antisense oligonucleotides

Country Status (5)

Country Link
EP (1) EP0865489A1 (en)
JP (1) JP2000501941A (en)
AU (1) AU1279397A (en)
CA (1) CA2239991A1 (en)
WO (1) WO1997021808A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216335A1 (en) * 2001-11-30 2003-11-20 Jennifer Lockridge Method and reagent for the modulation of female reproductive diseases and conditions
US7087580B2 (en) 1998-04-23 2006-08-08 Genesense Technologies, Inc. Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
FR2793798A1 (en) * 1999-05-21 2000-11-24 Inst Nat Sante Rech Med Antisense oligonucleotide, useful for treating e.g. cancer or restenosis, is directed against the translational elongation factor gene
CA2397919A1 (en) * 2000-01-19 2001-07-26 Parkash S. Gill Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides
AU2006233188B2 (en) * 2000-01-19 2008-01-24 Parkash S Gill Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2213738B1 (en) * 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
MX2013000986A (en) 2010-07-28 2013-07-03 Alcon Res Ltd Sirna targeting vegfa and methods for treatment in vivo.
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides

Also Published As

Publication number Publication date
JP2000501941A (en) 2000-02-22
CA2239991A1 (en) 1997-06-19
WO1997021808A1 (en) 1997-06-19
EP0865489A1 (en) 1998-09-23

Similar Documents

Publication Publication Date Title
AU9023798A (en) Mdm2-specific antisense oligonucleotides
AU5317496A (en) Single-stranded circular oligonucleotides
GB9510718D0 (en) Antisense oligonucleotides
AU7286696A (en) Antisense oligomers
AU3222795A (en) Antitumor antisense oligonucleotides
AU7205596A (en) Selective binding complementary oligonucleotides
AU5441896A (en) Cooperative oligonucleotides
GB9521124D0 (en) Dispenser
AU3811897A (en) Antisense oligonucleotides as antibacterial agents
GB9526386D0 (en) Dispenser
AU5259498A (en) Antisense oligonucleotides
GB9505438D0 (en) Antisense oligonucleotides
AU1279397A (en) Modified vegf antisense oligonucleotides
AU5645396A (en) Ascomycins
PL325283A1 (en) Dropd dispenser
AU3340797A (en) Modified oligonucleotides
AU6186398A (en) Process for selecting anti-sense oligonucleotides
AU128366S (en) Dispenser
AU6328498A (en) Oligonucleotides specific for the (marorab) operon
GB2302320B (en) Dispenser
AU128076S (en) Dispenser
AU5654096A (en) Antisense peptides
GB9506051D0 (en) Gene expression
AU6728696A (en) Strand orientation sensing
AU5314999A (en) Modified oligonucleotides